Westlake Chemical Corporation is a global maker and marketer of basic chemicals, vinyls, polymers and building products. The company has market cap of $7.85 billion. The Company’s products include a range of chemicals, which are fundamental to various consumer and industrial markets, including flexible and rigid packaging, automotive products, coatings, water treatment, refrigerants, residential and commercial construction, as well as other durable and non-durable goods. It has a 20.7 P/E ratio. The Company’s divisions include Olefins and Vinyls.
Fresenius Medical Care AG & Co. (ADR) (FMS) formed triangle with $39.10 target or 8.00% below today’s $42.50 share price. Fresenius Medical Care AG & Co. (ADR) (FMS) has $26.39 billion valuation. About 5,605 shares traded. Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) has declined 5.91% since September 8, 2016 and is downtrending. It has underperformed by 12.68% the S&P500.
Among 6 analysts covering Fresenius Medical (NYSE:FMS), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Fresenius Medical had 8 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 4 by RBC Capital Markets. The rating was maintained by Goldman Sachs with “Buy” on Tuesday, September 22. On Friday, July 8 the stock rating was upgraded by Jefferies to “Hold”. The rating was upgraded by Goldman Sachs to “Buy” on Thursday, September 3. The rating was upgraded by JP Morgan on Monday, January 4 to “Overweight”. Societe Generale downgraded the stock to “Buy” rating in Thursday, August 13 report. The rating was initiated by Nomura with “Buy” on Thursday, March 17. The rating was maintained by RBC Capital Markets with “Sector Perform” on Friday, July 31.
Analysts await Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) to report earnings on May, 2. They expect $0.44 EPS, up 18.92% or $0.07 from last year’s $0.37 per share. FMS’s profit will be $273.21M for 24.15 P/E if the $0.44 EPS becomes a reality. After $0.63 actual EPS reported by Fresenius Medical Care AG & Co. (ADR) for the previous quarter, Wall Street now forecasts -30.16% negative EPS growth.
Ratings analysis reveals 70% of Westlake Chemical’s analysts are positive. Out of 10 Wall Street analysts rating Westlake Chemical, 7 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $52 while the high is $78. The stock’s average target of $60.50 is -4.30% below today’s ($63.22) share price. WLK was included in 20 notes of analysts from July 24, 2015. The firm has “Buy” rating given on Wednesday, June 15 by Suntrust Robinson. SunTrust upgraded the stock to “Buy” rating in Wednesday, June 15 report. The firm has “Neutral” rating by Nomura given on Friday, July 24. JP Morgan maintained it with “Overweight” rating and $56 target in Tuesday, August 16 report. The firm earned “Buy” rating on Thursday, February 9 by Citigroup. Deutsche Bank maintained Westlake Chemical Corporation (NYSE:WLK) rating on Thursday, September 17. Deutsche Bank has “Hold” rating and $57 target. The stock of Westlake Chemical Corporation (NYSE:WLK) has “Outperform” rating given on Friday, January 8 by Cowen & Co. Cowen & Co maintained the shares of WLK in report on Monday, June 13 with “Outperform” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Monday, June 13. RBC Capital Markets maintained Westlake Chemical Corporation (NYSE:WLK) on Wednesday, August 5 with “Outperform” rating.
Since January 1, 0001, it had 0 insider purchases, and 9 sales for $7.04 million activity.
About 33,528 shares traded. Westlake Chemical Corporation (NYSE:WLK) has risen 20.71% since September 8, 2016 and is uptrending. It has outperformed by 13.94% the S&P500.
Analysts await Westlake Chemical Corporation (NYSE:WLK) to report earnings on May, 2. They expect $0.83 EPS, down 11.70% or $0.11 from last year’s $0.94 per share. WLK’s profit will be $103.06M for 19.04 P/E if the $0.83 EPS becomes a reality. After $0.87 actual EPS reported by Westlake Chemical Corporation for the previous quarter, Wall Street now forecasts -4.60% negative EPS growth.
